1. Home
  2. ENTX vs WIMI Comparison

ENTX vs WIMI Comparison

Compare ENTX & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.85

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo WiMi Hologram Cloud Inc.

WIMI

WiMi Hologram Cloud Inc.

HOLD

Current Price

$1.04

Market Cap

18.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
WIMI
Founded
2010
2015
Country
Israel
China
Employees
N/A
86
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
18.9M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ENTX
WIMI
Price
$2.85
$1.04
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
357.7K
100.2K
Earning Date
05-14-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.22
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.23
$1.24
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$1.07
52 Week High
$4.20
$5.65

Technical Indicators

Market Signals
Indicator
ENTX
WIMI
Relative Strength Index (RSI) 46.09 27.67
Support Level $2.73 N/A
Resistance Level $3.10 $1.43
Average True Range (ATR) 0.22 0.08
MACD -0.06 -0.03
Stochastic Oscillator 9.53 0.00

Price Performance

Historical Comparison
ENTX
WIMI

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

Share on Social Networks: